A characteristic feature of neoplastic transformation is a perpetual activation of oncogenic proteins. Here, we studied signal transducers and activators of transcription (STAT) in patients with mycosis fungoides (MF)/cutaneous T-cell lymphoma (CTCL). Malignant lymphocytes in dermal infiltrates of CTCL tumors showed frequent and intense nuclear staining with anti-PY-STAT3 antibody, indicating a constitutive activation of STAT3 in vivo in tumor stages. In contrast, only sporadic and faint staining was observed in indolent lesions of patch and plaque stages of MF. Moreover, neoplastic lymphocytes in the epidermal Pautrier abscesses associated with early stages of MF did not express activated STAT3. To address the role of STAT3 in survival/apoptosis, CTCL tumor cells from an advanced skin tumor were transfected with either wild-type STAT3 (STAT3wt) or dominant-negative STAT3 (STAT3D). Forced inducible expression of STAT3D triggered a significant increase in tumor cells undergoing apoptosis, whereas forced expression of STAT3wt or empty vector had no effect. In conclusion, a profound in vivo activation of STAT3 is observed in MF tumors but not in the early stages of MF. Moreover, STAT3 protects tumor cells from apoptosis in vitro. Taken together, these findings suggest that STAT3 is a malignancy factor in CTCL.
Introduction
Mycosis fungoides (MF) belongs to the spectrum of cutaneous Tcell lymphomas (CTCL). It evolves in the skin and usually runs a protracted, indolent course, but progresses with the development of cutaneous tumors after a variable period of time. The most common and often the first cutaneous manifestations are flat, erythematous, and well-circumscribed macules (the patch stage); slightly infiltrated plaques in more progressive stages (the plaque stage); and eventually nodules and tumors often ulcerated in the latest stage (the tumor stage). The various cutaneous manifestations, patches, plaques, and tumors may be present simultaneously in a patient and in rare patients, tumors may be the presenting cutaneous lesion. The malignant cells of MF are mostly CD4 þ lymphocytes, but variants with a CD8 þ phenotype are seen. The course of MF is usually indolent and will progress over years, but the prognosis is drastically worsened with the development of tumors and disease dissemination extracutaneously to lymph nodes and other organs. [1] [2] [3] Cytokines bind specific cell surface receptors and activate intracellular signal transduction pathways, often involving the Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway. The JAK proteins comprise a family of nonreceptor tyrosine kinases that are constitutively associated with cytoplasmic membrane-proximal regions of various receptors. Upon ligand binding, JAKs become catalytically activated and phosphorylate tyrosine residues in the receptor complex, creating docking sites for SH2 domain containing proteins. Among the recruited proteins are STAT transcription factors that, upon tyrosine phosphorylation by JAKs, homo-or heterodimerize and translocate to the nucleus where they trigger transcription of target genes (reviewed in Heim 4 and Levy and Darnell 5 ). The etiology of MF/CTCL is unknown. However, recent evidence suggests that disturbances in intracellular signaling pathways play a role in the pathogenesis. Constitutive activation of STAT3 is a characteristic feature of malignant cell lines derived from the skin and blood from CTCL patients.
6-10 STAT3 activation is induced by a large number of cytokines and has been implicated in the regulation of many cellular processes, including cell division, differentiation, survival, and cytokine production (reviewed in Benekli . A constitutive SOCS3 expression has been reported in CTCL cell lines and was found to be mediated by the constitutive STAT3 activation. 16 The importance of controlling STAT3 activation has been illustrated by the observation that a constitutively activated form of STAT3 induces uncontrolled cellular growth in vitro and functions as an oncogene in vivo. 17 Here, we show that STAT3 is activated in vivo in malignant lymphocytes of tumor lesions from MF patients, but not in the more indolent lesions of patches and plaques. This suggests that the activation of STAT3 may herald a transition from an indolent to a more aggressive course of the disease. Furthermore, we provide evidence that STAT3 activation is involved in the protection against spontaneous apoptosis in CTCL cells, suggesting that STAT3 plays an important role in the pathogenesis of CTCL. STAT3 may, therefore, represent a novel therapeutic target in CTCL, particularly at the more advanced stage of the disease.
Material and methods

Antibodies and other reagents
Hemaglutinin (HA) monoclonal antibody (mAb) was from BabCO (Richmond, CA, USA). Myc (9E10), SOCS3 (M-20), and ERK1/2 (K-23) antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). STAT3 antibody was from New England BioLabs (Hertfordshire, UK). Phosphospecific STAT3 (tyr705) mAb was from nanoTools (Denzlingen, Germany). FITC-labeled rabbit anti-mouse antibody (Ab), FITC-labeled rabbit anti-goat Ab, biotinylated goat anti-rabbit Ab, and HRPconjugated streptavidin were from DakoCytomation (Glostrup, Denmark). DNA binding dye 7-amino-actinomycin D (7-AAD) was from Sigma (St Louis, MO, USA).
Patients
Eight patients with histologically proven MF/CTCL, three females and five males, were examined. Their mean age was 67 years, range 23-84 years, and the mean duration of their disease was 7.6 years, range 3 months to 20 years. Four patients had tumors, and also plaque and patch lesions; one patient developed anaplastic large T-cell lymphoma, whereas two patients had patch lesions only ( Table 1 ).
The diagnosis of MF was established in all patients based on clinical morphology and histological evaluation of hematoxylin-eosin (HE)-stained sections. 18 Three patients, all in the tumor stage, died from their disease. No patients were cured (Table 1) .
Patients with common inflammatory skin diseases characterized histologically by predominant cutaneous lymphocytic infiltrates, such as lichen planus, contact dermatitis, psoriasis, pseudolymphoma/insect bite, and gyrate erythema, served as controls.
Specimens
In all, 31 4-mm punch biopsies from the eight patients were taken from different skin lesions, synchronously or metachronously (12 patch lesions, eight plaque lesions, 11 tumors). In all patients, each type of MF lesions was recorded (patch, plaque, tumor), but not every lesion was biopsied ( Table 1 ). The biopsies were fixed in formalin and embedded in paraffin. Punch biopsies (4 mm) from the patients with inflammatory skin disorders were treated identically.
Cell lines
The MF/CTCL cell lines have been extensively described elsewhere.
19 MF2000 cells were centrifuged and the pellet was either mounted directly on glass slides and formalin fixed or resuspended in gelatin, formalin fixed, paraffin embedded, and cut. In parallel, MF2000 cells were transfected with wild-type STAT3 (STAT3wt), dominant-negative STAT3 (STAT3D), wildtype SOCS3 (SOCS3wt), and an empty vector. The transfected cells were maintained in RPMI 1640 (Sigma Chemical, St Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS) (Life Technologies, Roskilde, Denmark), 2 mM L-glutamine (Sigma), 100 mg/ml penicillin/streptomycin (Sigma) and 70 mg/ ml Zeocin (Invitrogen, Taastrup, Denmark). Prior to quantification of apoptotic cells by flow cytometry, the cells were grown in medium supplemented with 0, 0.1, 1, or 10% FBS.
Immunohistochemistry
Prior to immunostaining, the cytospins were fixed in 4% neutralbuffered formaldehyde for 15 min followed by 5 min permeabilization in 0.5% Triton X-100 in TBS. Antigen retrieval was performed on the paraffin sections by boiling for 15 min in Target Retrieval Solution (DakoCytomation, Glostrup, Denmark). Cytospins and paraffin sections were incubated overnight. Working concentrations of the primary antibodies of 1:800 and 1:1600 were chosen. The detection of antibody binding was accomplished by using the Labelled SteptAvidin Biotin detection system (DakoCytomation) with amino-ethylcarbazol as chromogen. Mayers hematoxylin was used for counter staining. 18 Transfections MF2000 were stably transfected with inducible wild-type HAtagged STAT3(STAT3wt), HA-tagged dominant-negative STAT3(-STAT3D), Myc-tagged wild-type SOCS3(SOCS3wt), or an empty vector control using the T-Rext system (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Human SOCS3wt construct was obtained by PCR cloning from cDNA from IL-2-stimulated human PLT cells. 20 STAT3wt and STAT3D have been described elsewhere. 21 In STAT3D, E434 and E435 have been replaced with alanines, rendering STAT3D unable to bind DNA. In brief, the stable transfections were performed by electroporation (240 V) using 25 mg DNA and the transfected cells were selected by limiting dilution in the medium containing 150 mg/ml Zeocin (Invitrogen, Taastrup, Denmark).
Protein extraction and Western blotting
Western blotting was performed essentially as described elsewhere. 22, 23 In brief, cells (1 Â 10 6 ) were incubated for 12 h (SOCS3wt) or 24 h (STAT3wt and STAT3D) with 20 ng/ml Tetracycline (Tet) (Invitrogen, Taastrup, Denmark). Cells were then pelleted, lysed in ice-cold lysis buffer, and subjected to Western blotting using the indicated antibodies. Blots were evaluated using enhanced chemiluminescence, stripped, and reprobed according to the manufacturer's manual (Amersham, Buckinghamshire, UK). In vivo activation of STAT3 in CTCL VH Sommer et al mAb followed by FITC-labeled rabbit anti-mouse Ab or primary anti-SOCS3 polyclonal antibody followed by FITC-labeled rabbit anti-goat Ab. Cells were fixed in 1% paraformaldehyde (Bie & Berntsen, Rødovre, Denmark) and analyzed on FACScan (Becton Dickinson).
Flow cytometry
Quantification of apoptotic cells
Apoptotic cells were quantified using the fluorescent 7-AAD as described in detail elsewhere. 10 Seven independent experiments were performed with MF2000 cells undergoing starvation. In brief, cells were cultured at 5 Â 10 5 cells/ml for 6 days in the media supplemented with 0, 0.1, 1, or 10% serum. The medium was changed when needed. The cells were stimulated with Tet every 24 h to induce the expression of STAT3D, STAT3wt, SOCS3wt, and/or empty vector control. Apoptosis was measured by 7-AAD staining every 24 h; 300 ml cell culture was harvested and incubated with 7-AAD prior to analysis on FACScan (Bector Dickinson).
Statistical analysis
Statistical differences were determined using a paired two-tailed t-test with significance levels at Po0.05. Following quantification of apoptotic cells, the data obtained from seven independent experiments were pooled and subjected to statistical analysis. The increase in apoptosis (Tet-induced cells compared to noninduced cells) following STAT3D induction was calculated.
Results
Tumor cell lines obtained from a skin biopsy from a patient with advanced MF expressed high levels of STAT3 in the cytoplasm and nucleus (Figure 1b ). More importantly, STAT3 was constitutively activated as evidenced by the clear staining with an antibody recognizing the phosphorylated (PY705) form of STAT3 (Figure 1c ). PY-STAT3 staining was mostly nuclear, which is in agreement with a nuclear translocation of phosphorylated STAT3 in these and other CTCL tumor cell lines. 6, 23 In contrast, STAT3 is neither constitutively phosphorylated on tyrosine nor located in the nucleus of nonmalignant Tcell lines from CTCL patients (cf. below) or patients with psoriasis vulgaris (data not shown).
To address whether the constitutive activation of STAT3 was seen in vivo, dermal lymphocytic infiltrates of patients with patch/plaque MF (and patients with inflammatory diseases) were examined for expression of the phosphorylated form of STAT3 (Figures 2 and 3) . The dermal lymphocytic infiltrates of patients with patch stage MF contained a few PY-STAT3-positive cells scattered throughout the infiltrates as was also observed in patients with inflammatory diseases (Figure 2c and data not shown). The staining was nuclear, but it was not possible to determine whether the positive cells of the MF biopsies were atypical (neoplastic) lymphocytes or infiltrating, reactive, nonmalignant lymphocytes (Figure 2a-c) . Importantly, the small collections of intraepidermal lymphocytes (Pautrier microabscesses; Figure 3a ) seen in most plaque MF lesions always stained negative for PY-STAT3 (Figure 3c ). Essentially identical results were obtained analyzing 20 biopsies from eight patients (data not shown). Since Pautrier microabscesses comprise the neoplastic rather than the reactive lymphocytes, and are a characteristic feature of MF, these findings suggest that STAT3 might not be constitutively activated at the pretumor stages of MF.
However, at the tumor stage, a distinctly different picture was seen. MF tumor lesions showed dense dermal lymphocytic infiltrates of varying but clearly recognizable nuclear atypia (Figure 4a ). More importantly, the atypical large cells, and to a lesser degree the smaller scattered cells, generally showed positive nuclear staining with anti-PY-STAT3 (Figure 4c) , indicating that the CTCL tumor cells acquired a constitutive (Figure 6a and 6, 10 ). The nuclei of the keratinocytes, mostly in the basal layers of the epidermis, were also stained in biopsies from both patients and controls. The intensity of keratinocyte staining with PY-STAT3 varied between biopsies, was usually rather weak, and did not discern between the MF patients and controls. These findings are in keeping with other reports that STAT3 is activated in proliferating keratinocytes. 24, 25 Previous studies have shown that STAT3 may be involved in both pro-and antiapoptotic responses. 26, 27 Given the conclusion above that STAT3 was constitutively activated in neoplastic lymphocytes in tumor lesions, we wished to determine whether STAT3 plays a role in the regulation of apoptosis and survival in CTCL cells. To do this, we took advantage of the T-Rext system that allows Tet-regulated expression of genes of interest in mammalian host cells, enabling us to study the effects of forced inducible expression of a STAT3D, STAT3wt, a downstream target of STAT3 (SOCS3wt), or an empty vector control. As shown in Figure 6b , stimulation with Tet induced STAT3wt, STAT3D, or SOCS3wt expression in transfected CTCL tumor cell lines. As expected, no reactivity with anti-tag (HA or Myc) antibodies was observed in cell lines transfected with the empty control vector (Figure 6b and data not shown). The expression of STAT3wt and STAT3D reached a maximum between 20 and 48 h, whereas high SOCS3 expression could be detected already at 10-12 h (data not shown). Endogenous STAT3 is constitutively phosphorylated on tyrosine in CTCL cell lines (Figure 6a and  6,9 ) . Accordingly, as shown in Figure 6b , the transfected forms of STAT3 (STAT3wt and STAT3D) also became tyrosine phosphorylated (Figure 6b , right, middle row), indicating that they were recognized by a STAT3 activating tyrosine kinase in CTCL cells. Flow cytometry using intracellular staining with anti-HA or anti-SOCS3 antibodies showed that STAT3wt and STAT3D were expressed at comparable levels, whereas no reactivity was observed in CTCL lines transfected with empty vector (Figure 6c ).
As expected, 16 tumor cells express high levels of endogenous SOCS3, whereas nonmalignant skin T cells from the same patient are essentially negative for endogenous SOCS3 (and PY-STAT3) (Figure 6a ). The apparent lack of expression of endogenous SOCS3, but high expression of exogenous SOCS3 in transfected cell lines (Figure 6b) , is caused by the fact that the exogenous SOCS3 is under the control of a very strong (CMV) promoter. Thus, Tet-stimulated cells express large amounts of SOCS3 (Figure 6b ). To avoid overexposure of exogenous SOCS3 in Tet-stimulated cells, low amounts of proteins have been loaded on the gel that, however, 'mask' the expression of endogenous SOCS3 (Figure 6b vs a) . Flow cytometry using intracellular staining with anti-SOCS3 antibodies confirmed A fraction of the tumor cells underwent spontaneous apoptosis during cell culture and after 24-48 h 10-15% of the tumor cells were apoptotic as determined by 7-AAD -staining and flowcytometry analysis (Figure 7a and data not shown). Forced expression of STAT3D induced a significant (Po0.05) increase in apoptosis, which was already apparent after 2-3 days of culture, but peaking at days 4-5 of culture (Figure 7a , STAT3D11 and STAT3D25). In contrast, forced expression of STAT3wt did not increase apoptosis, but induced an insignificant decrease in apoptosis (Figure 7a, STAT3wt) . Likewise, forced expression of SOCS3, a downstream target of STAT3, had no effect on the degree of apoptosis (Figure 7a, SOCS3wt) . Essentially identical results were obtained in seven independent experiments (data not shown). To address whether the effect of STAT3 inhibition was dependent on the growth conditions, tumor cells were grown at different serum concentrations. The level of spontaneous apoptosis varied between different growth conditions, but the relative increase in apoptosis was relatively constant, that is, between 30 and 50% (Figure 7a+b ). Essentially similar results were obtained in independent experiments using different cell lines transfected with STAT3D (eg STAT3D11 and Figure 7b and data not shown), indicating that the increase in apoptosis was an effect of STAT3D per se and not an isolated feature of one peculiar transfectant.
STAT3D25 in
Discussion
The present study provides the first evidence of an in vivo activation of STAT3 in CTCL tissues. Accordingly, atypical lymphocytes in the dermal infiltrates of MF tumors generally stained strongly positive with an mAb recognizing the activated form of STAT3 (PY-STAT3). Morphologically the binding was mostly, but not exclusively, nuclear, that is, very similar to the findings previously described in CTCL tumor cell lines (Figure 1c and 6, 23 ). The staining patterns in early stages of MF were less clear. Activation of STAT3 was observed in dermal lymphocytes, but the staining was sporadic and faint. Since most of the lymphocytes in early MF lesions are inflammatory, rather than neoplastic, and the cellular atypia of the neoplastic cells is limited, one should consider that the inflammatory, rather than malignant lymphocytes, could contain activated STAT3 in these early MF stages. The dermal pattern of PY-STAT3 staining in patch and plaque stages of MF resembled the staining pattern in the biopsies from inflammatory skin diseases (data not shown), supporting this possibility. On morphological grounds it would be difficult, however, to exclude that some of the stained dermal lymphocytes were MF cells with the capacity of constitutive STAT3 activation. The finding of negative staining of the lymphocytes in epidermal Pautrier microabscesses, which are generally accepted to be neoplastic cells with strong epidermotropism, strongly suggest that STAT3 is not constitutively activated in MF cells at this early stage.
In contrast, the morphologically atypical tumor-forming malignant cells of MF seemed to have acquired constitutive STAT3 activation similar to the one typically seen in the CTCLderived cell lines. 6, 9, 23 It is well known that in early MF stages, the disease may run an indolent course over years, whereas the advent of tumors changes the prognosis abruptly with impaired response to treatment, extracutaneous dissemination, and eventually a fatal outcome.
1-3 Interestingly, Zhang et al 8, 9 were able to demonstrate only a transient STAT3 activation in lymphocyte cultures from patients with a low-grade CTCL and the constitutive STAT3 activation only in cells corresponding to the advanced, late-stage of the disease. Taken together, these findings suggest that a constitutive STAT3 activation is a hallmark of malignant progression in MF.
In order to address how constitutive activation of STAT3 might contribute to malignant transformation in CTCL, a STAT3D was induced in CTCL cell lines obtained from a late-stage MF/CTCL tumor. Forced expression of STAT3D induced a significant (Po0.05) increase in apoptosis, whereas forced expression of STAT3wt, SOCS3wt, or empty vector had no such effect, suggesting that STAT3 delivers antiapoptotic signals in CTCL cells. This conclusion is in keeping with other reports that STAT3 has antiapoptotic functions in certain models (reviewed in Levy and Lee 12 and Battle and Frank 26 ) and that inhibition of STAT3 activation by a JAK inhibitor triggers apoptosis in CTCL cells. 7, 10 It has previously been reported that stable noninducible expression of STAT3D in MF2000 cells blocks IL-5 production and strongly inhibits IL-13 production. 22 However, these cells do not seem to be more prone to apoptosis than wild-type cells. This apparent paradox might be explained by the fact that the persistent presence of STAT3D in these cells confers a selective pressure that favors the clones capable of surviving the elevated STAT3D expression. Therefore, induced expression of STAT3D seems to be a better way of studying apoptosis in cancer cells. Even though STAT3 has been shown to be proapoptotic in some experimental models, 28, 29 the antiapoptotic effects of STAT3 activation have been extensively described in many different cell lines and cancers. It was demonstrated that the IL-6-induced In vivo activation of STAT3 in CTCL VH Sommer et al prevention of apoptosis in T cells is mediated through STAT3 activation. 30 Likewise, STAT3 was shown to be required for gp130 receptor-induced antiapoptotic effects in a pro-B cell line. 31 Moreover, it was observed that constitutive STAT3 activation in human myeloma cells and in head and neck cancer suppressed apoptosis. 32, 33 Altogether, these data support our present finding that constitutively activated STAT3 may confer an advantage to cancer cells by preventing apoptosis.
The coexistence of a constitutively activated Jak3/STAT3 pathway and high levels of SOCS3 expression in CTCL tumor cells comprise a paradox of CTCL tumors (Brender et al. Leukemia, submitted) . It was previously shown that inhibition of Jak3 blocks STAT3 activation and SOCS3 expression and triggers apoptosis in CTCL tumor cells. 6, 10, 16 The lack of effect of SOCS3 on Jak3/STAT3 activation is not due to mutations in SOCS3, STAT3, or Jak3 and forced overexpression of SOCS3 does not inhibit STAT3 activation (Brender et al. Leukemia, submitted) . Studies are in progress to address whether Jak3/ STAT3 activation is mediated by an SOCS3-resistant oncogenic kinase.
In conclusion, we provide the first evidence that STAT3 is constitutively activated in vivo in the tumor stage of MF/CTCL and that this activation might be involved in the resistance of tumor cells to undergo apoptosis. Accordingly, we propose that STAT3 activation is possibly involved in the neoplastic transformation in CTCL and may, therefore, be a molecular target for therapeutic interventions in the treatment of this disease, particularly at the more advanced stage. 
